See every side of every news story
Published loading...Updated

FDA places clinical hold on Verve Therapeutics gene-editing treatment

Summary by Ground News
Verve Therapeutics says its experimental gene-editing treatment for a common form of heart disease was placed on clinical hold by the FDA. The Cambridge, Mass.-based biotech had submitted a request to the FDA in October to allow participants in the U.S. to receive the CRISPR-based treatment.

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

STAT broke the news in Boston, United States on Monday, November 7, 2022.
Sources are mostly out of (0)